US guidelines for the use of antiretroviral agents in paediatric HIV infection revised (2006)
The Guidelines for the Use of Antiretroviral Agents in Paediatric HIV Infection have also been revised. The revision represents a major rewriting of the main document to improve its organisation and readability. Because the main document has been almost completely rewritten, there is no highlighting of changes to either its text or tables.
The documents Appendix: Characteristics of Available Antiretroviral Drugs, and Supplement I: Paediatric Antiretroviral Drug Information, have also been updated. Changes to those sections appear highlighted in yellow.
Changes in recommendations include:
- Revised guidelines on when to initiate therapy in antiretroviral-naive children, with recommendations for four age categories (< 12 months, 1 to < 4 years, 4 to 12 years, and > 13 years).
- Revised discussion and tables of rationale for antiretroviral drug choice for antiretroviral-naive children, with revised preferred and alternative treatment regimen recommendations.
- Revised recommendations for adolescents, including issues related to drug dosing, use of contraception, pregnancy, and transition into adult care.
- Updated Characteristics of Available Antiretroviral Drugs drug dosing appendix and updated Supplement I: Paediatric Antiretroviral Drug Information, including information on newly approved antiretroviral agents, such as darunavir, and new paediatric studies.
- Recommendations for antiretroviral resistance testing for all antiretroviral-naive children prior to initiation of antiretroviral therapy.
- New section and table on monitoring of children on antiretroviral therapy and management of antiretroviral toxicity/intolerance.
- New section on management of the treatment-experienced child.
- New section and tables on assessment and management of antiretroviral treatment failure and choice of new antiretroviral regimen in children with treatment failure.
- New section on therapeutic drug monitoring.
- New section on discontinuation or interruption of antiretroviral therapy.
- Inclusion of darunavir information.
The updated guidelines are available on the Paediatric Guidelines page of the Clinical Guidelines section of AIDSinfo:
Source: FDA listserv